Clinical trials
Pancreatic Adenocarcinoma Advanced or Metastatic clinical trials
Below are recruiting pancreatic adenocarcinoma advanced or metastatic clinical trials, each written for real people, not researchers. We’re tracking 3,884 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05620017RecruitingPhase 1
Early test of an injection for advanced solid tumors
This Phase 1 study tests BAT8008 injection to see how safe it is, how well the body handles it, and how it affects the body’s drug levels. It’s for adults with advanced or metastatic solid tumors that are not responding to, or can’t be tolerated with, standard treatments.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT05398861RecruitingPhase 2
Testing utidelone plus bevacizumab for HER2-negative advanced breast cancer
This trial studies whether utidelone combined with bevacizumab can shrink tumors and slow progression in women with advanced HER2-negative breast cancer that has already been treated at least twice. It may help people who have limited options after earlier chemotherapy and/or hormone (endocrine) treatments.
Zhengzhou, HenanAges 18–70 - NCT05400967RecruitingEarly Phase 1
Scan metastatic tumors and test targeted radiation treatment
This trial looks at whether a special PET scan can find metastatic tumors and guide a targeted radiation treatment. It may help people by improving how doctors locate tumors and decide where to deliver therapy.
Beijing, Beijing MunicipalityAges 18–80 - NCT05513716Recruiting
Study of colorectal cancer spread in the belly lining
This study looks at colorectal cancer that has spread to the peritoneum (the lining around the belly) using existing tumor tissue samples. It may help researchers better understand the cancer’s biology and improve future treatments.
ManchesterAges 18 years+ - NCT05471856RecruitingPhase 1
Test different doses of cancer drugs with ezabenlimab
This Phase 1 trial tests how different doses of a study drug (BI 1703880) work and how safe they are when given with ezabenlimab for advanced solid tumors. It’s for people whose cancer can’t be removed with surgery and who have tried standard treatments or can’t get them.
Los Angeles, CaliforniaAges 18 years+ - NCT05430373RecruitingPhase 1
Injection study for advanced solid tumors using tumor-fighting cells
This Phase 1 trial tests GT101, an injection made from your own tumor-fighting immune cells, for advanced solid cancers that can’t be removed with surgery. It’s mainly aimed at checking safety and early signs of whether the treatment may work.
Beijing, Beijing MunicipalityAges 18–70 - NCT05464082RecruitingPhase 2
Collect tumor samples to guide early breast cancer recurrence care
This Phase 2 study tests a “precision” approach using tumor sample testing to help predict, prevent, and treat early metastatic recurrence in triple-negative or hormone-receptor–low, HER2-negative breast cancer. If you qualify, you’ll be asked to provide tumor tissue before (or in place of) standard chemotherapy, so researchers can learn which tumor features matter most.
Salt Lake City, UtahAges 18 years+ - NCT04891198RecruitingPhase 2
Envafolimumab for advanced cancers after other treatments
This trial tests envafolimumab, an immune therapy given alone, in people with advanced solid tumors that can’t be removed by surgery or have spread. It’s for patients whose cancer has grown despite (or they couldn’t tolerate) standard treatment, and it aims to find whether this drug can shrink tumors or slow growth.
BeijingAges 18 years+ - NCT05075512RecruitingPhase 2
Anlotinib with fulvestrant for advanced, HR-positive, HER2-negative breast cancer
This trial studies whether adding anlotinib (a targeted medicine) to fulvestrant (a hormone-blocking injection) can improve outcomes for people with advanced HR-positive, HER2-negative breast cancer. It focuses on safety and effectiveness when cancer has returned or progressed after hormone treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT05057052RecruitingPhase 2
Freezing liver tumors with immunotherapy and a pill drug
This Phase 2 trial tests whether freezing (cryoablation) plus sintilimab (an immune system medicine) and regorafenib (a pill) can shrink colorectal cancer that has spread to the liver. It is for people whose cancer has come back or progressed after at least two prior chemotherapy treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05248581Recruiting
Living donor liver transplant for unresectable colon cancer spread
This trial looks at using a living donor liver transplant for people whose colon or rectal cancer has spread to the liver in a way that can’t be removed with standard surgery. It may help if you might otherwise have limited options because your liver surgery would be too risky.
Rochester, New YorkAges 18 years+ - NCT05109208Recruiting
Ultrasound check for erection recovery after prostate surgery
This study looks at whether ultrasound imaging can help understand and improve erectile function after prostate removal surgery that aims to protect the nerves. If you’re interested in keeping or improving erections, your ultrasound results may be used to guide follow-up care.
Rochester, MinnesotaAges 40 years+ - NCT05260385RecruitingPhase 1/Phase 2
Study drug KC1036 for advanced digestive cancers
This early-phase study tests whether KC1036 can treat advanced digestive system cancers that have come back or spread after standard treatment. It may help people by shrinking tumors or slowing growth, and it will also check safety and side effects.
BeijingAges 18–75 - NCT05420779RecruitingPhase 2
TSL-1502 for breast cancer with BRCA gene mutations
This Phase 2 trial tests TSL-1502 capsules, a targeted medicine for breast cancer, in people whose blood test shows a harmful BRCA gene mutation. It aims to see whether it can control the cancer and how safe it is after prior treatment.
BeijingAges 18–75 - NCT05222087RecruitingPhase 1
Radiation for newly diagnosed metastatic lung cancer without driver mutations
This early study tests whether a specific kind of radiation can be safely given to people with newly diagnosed metastatic lung cancer when cure isn’t possible. It’s meant to see how well the treatment can be delivered and how it affects outcomes in a specific genetic group of tumors.
Southport, QueenslandAges 18 years+ - NCT05256745RecruitingPhase 1/Phase 2
A medicine to protect the heart during breast cancer chemotherapy
This early-phase study tests azeliragon to lower the risk of chemotherapy-related heart damage in women with early-stage breast cancer. Participants get their planned standard chemotherapy, plus the study medicine, and are monitored for safety and heart health.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04819243RecruitingPhase 2
Test a BRCA-targeted drug plan for advanced ER-positive breast cancer
This Phase 2 study tests how well a treatment plan using palbociclib followed by talazoparib (and possibly atezolizumab) works in certain people with advanced ER-positive breast cancer. It may help by targeting cancer biology linked to BRCA/HRD changes and by strengthening how the cancer is controlled.
Seoul, Gannam-guAges 19 years+ - NCT06767306RecruitingPhase 2
SBRT radiation plus immunotherapy for limited spread melanoma
This trial tests if combining targeted radiation (SBRT) with standard immunotherapy works better for melanoma that has spread to a few spots in the body (but not the brain). It is for people who have not yet had treatment for their current spread.
Westmead, New South WalesAges 18 years+ - NCT04938986Recruiting
Testing a tumor marker to predict colon cancer relapse risk
This study looks at whether a lab test on your tumor can better predict the chance that non-metastatic colon cancer will come back after surgery. Researchers will compare relapse risk using the Immunoscore® test to help guide follow-up and treatment decisions.
MarseilleAges 18–80 - NCT04928612RecruitingPhase 1
CBP-1018 for advanced cancers that no standard treatment helped
This early-phase study tests CBP-1018 in people with advanced solid tumors, such as prostate, kidney, or certain lung cancers. It aims to see how the drug works and whether it’s safe enough to continue studying.
Guangzhou, GuangdongAges 18 years+ - NCT04838899Recruiting
Radiation for limited, progressing prostate cancer on abiraterone
This study tests whether a very focused type of radiation (SABR) can control a small number of prostate cancer spots that are starting to grow while you’re already on abiraterone. It may help by treating only the areas that are progressing, while other areas remain controlled.
Toronto, OntarioAges 18 years+ - NCT06730659RecruitingPhase 1
CHT101 for CD70-positive advanced solid tumors
This study tests a new drug called CHT101 for people with advanced solid tumors that have a specific protein (CD70) on the cancer cells. It may be an option if standard treatments have already been tried and failed.
TianjinAges 18–70 - NCT04643418RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors you can’t remove
This trial tests MPB-1734, a new study drug, in adults with advanced solid tumors that can’t be removed and for which standard treatment has stopped working. It aims to find out how safe it is and whether it can shrink or control the cancer.
TaipeiAges 18 years+ - NCT04254263RecruitingPhase 3
Pyrotinib after breast cancer therapy for HER2-positive early disease
This trial studies whether adding pyrotinib after standard treatment helps prevent breast cancer from coming back in people with HER2-positive early-stage breast cancer. You may be eligible if you finished chemotherapy plus trastuzumab and still had signs of cancer in the tissue removed during surgery.
Shanghai, Shanghai MunicipalityAges 18–70
Hear when a new Pancreatic Adenocarcinoma Advanced or Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic adenocarcinoma advanced or metastatic?
- Yes. Clin2 currently lists 3,884 recruiting pancreatic adenocarcinoma advanced or metastatic studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic adenocarcinoma advanced or metastatic trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic adenocarcinoma advanced or metastatic trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Pancreatic Adenocarcinoma
- Locally Advanced Pancreatic Adenocarcinoma
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.